[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. W. Marc Hertz Ph.D.", "age": 52, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 842014, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leanne M. Kelly", "age": 46, "title": "CFO & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 550930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vipin  Kumar Chaturvedi Ph.D.", "age": 63, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Albert  Agro Ph.d.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.439, "open": 0.4489, "dayLow": 0.4208, "dayHigh": 0.4489, "regularMarketPreviousClose": 0.439, "regularMarketOpen": 0.4489, "regularMarketDayLow": 0.4208, "regularMarketDayHigh": 0.4489, "volume": 38246, "regularMarketVolume": 38246, "averageVolume": 413421, "averageVolume10days": 138640, "averageDailyVolume10Day": 138640, "marketCap": 1369696, "fiftyTwoWeekLow": 0.412, "fiftyTwoWeekHigh": 62.23, "fiftyDayAverage": 0.6827, "twoHundredDayAverage": 7.017625, "currency": "USD", "enterpriseValue": -424304, "floatShares": 3061948, "sharesOutstanding": 3196490, "sharesShort": 18259, "sharesShortPriorMonth": 115733, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0057, "heldPercentInsiders": 0.0418, "heldPercentInstitutions": 0.0086, "shortRatio": 0.14, "shortPercentOfFloat": 0.0057, "impliedSharesOutstanding": 3196490, "bookValue": 0.401, "priceToBook": 1.0685786, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -13037000, "trailingEps": -28.25, "lastSplitFactor": "1:7", "lastSplitDate": 1706572800, "enterpriseToEbitda": 0.038, "52WeekChange": -0.9920511, "SandP52WeekChange": 0.23099434, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "messageBoardId": "finmb_136941170", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4285, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 1808000, "totalCashPerShare": 0.566, "ebitda": -11133000, "totalDebt": 14000, "quickRatio": 0.67, "currentRatio": 1.088, "debtToEquity": 5.405, "returnOnAssets": -4.16929, "freeCashflow": -5195875, "operatingCashflow": -8990000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]